Xenon Pharmaceuticals Inc. 4
4 · Xenon Pharmaceuticals Inc. · Filed Nov 12, 2014
Insider Transaction Report
Form 4
STEIN EVAN A.
Director
Transactions
- Conversion
Common Shares
2014-11-09+1,038,964→ 1,038,964 total(indirect: By Lipoterx, Ltd.) - Conversion
Common Shares
2014-11-09+967→ 967 total(indirect: By LLC) - Conversion
Series B Preferred Shares
2014-11-09−967→ 0 total(indirect: By LLC)→ Common Shares (967 underlying) - Conversion
Series E Preferred Shares
2014-11-09−1,038,964→ 0 total(indirect: By Lipoterx, Ltd.)→ Common Shares (1,038,964 underlying)
Footnotes (4)
- [F1]The Series B Preferred Shares converted into Common Shares on a 1-for-1 basis immediately prior to the completion of the Issuer's initial public offering of Common Shares and had no expiration date.
- [F2]These shares are held by the Stein Family LLC, for which the Reporting Person serves as the managing member.
- [F3]The Series E Preferred Shares converted into Common Shares on a 1.2-for-1 basis immediately prior to the completion of the Issuer's initial public offering of Common Shares and had no expiration date.
- [F4]These shares are held by Lipoterx, Ltd. ("Lipoterx"). Lipoterx Holdings, LLC, the general partner of Lipoterx, has sole voting and investment power with respect to the shares held by Lipoterx. The Reporting Person, the managing partner of Lipoterx Holdings, LLC has sole voting and investment power with respect to the shares held by Lipoterx.